beta-thalassemia

Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients
Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients
Endpoints
Bluebird Bio
beta-thalassemia
gene therapy
Flag link:
Bluebird Reports Early Results From Upgraded Gene Therapy
Bluebird Reports Early Results From Upgraded Gene Therapy
Xconomy
Bluebird Bio
LentiGlobin
gene therapy
clinical trials
beta-thalassemia
Flag link:
Sangamo to transfer two gene therapies to Biogen spin-off
Sangamo to transfer two gene therapies to Biogen spin-off
BioPharma Dive
Sangamo
gene therapy
Biogen
Bioverativ
sickle cell disease
beta-thalassemia
Flag link:
Bluebird Shares Plunge on Waning Effect of Old Gene Therapy
Bluebird Shares Plunge on Waning Effect of Old Gene Therapy
TheStreet.com
Bluebird Bio
gene therapy
beta-thalassemia
Flag link:
3 Clinical Trials to Watch As Bluebird Bio Rounds Out 2015
3 Clinical Trials to Watch As Bluebird Bio Rounds Out 2015
Motley Fool
clinical trials
Bluebird Bio
HGB-205
HGB-206
HGB-204
sickle cell disease
beta-thalassemia
Flag link:
What's in bluebird bio's Pipeline That Has Investors So Excited?
What's in bluebird bio's Pipeline That Has Investors So Excited?
Motley Fool
Bluebird Bio
gene therapy
LentiGlobin
beta-thalassemia
sickle cell disease
Flag link:
A pair of Celgene partners gets on the FDA fast track
A pair of Celgene partners gets on the FDA fast track
Fierce Biotech
Celgene
FDA
fast track
luspatercept
Acceleron
beta-thalassemia
AG-120
Agios Pharmaceuticals
Flag link:
Gene therapy pioneer Bluebird bags a 'breakthrough' title for lead program
Gene therapy pioneer Bluebird bags a 'breakthrough' title for lead program
Fierce Biotech
Bluebird Bio
gene therapy
beta-thalassemia
LentiGlobin BB305
Flag link:
Bluebird Stock Rockets On Gene Therapy Results
Bluebird Stock Rockets On Gene Therapy Results
Forbes
Bluebird Bio
beta-thalassemia
Flag link:
Biogen to Develop Blood Medicines in Deal With Sangamo
Biogen to Develop Blood Medicines in Deal With Sangamo
Bloomberg
Biogen Idec
Sangamo BioSciences
beta-thalassemia
sickle cell disease
Flag link:
Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute for Regenerative Medicine (CIRM) to Develop ZFP Therapeutic for Beta-thalassemia
Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute for Regenerative Medicine (CIRM) to Develop ZFP Therapeutic for Beta-thalassemia
Yahoo/PR NewsWire
Sangamo BioSciences
beta-thalassemia
stem cells
ZFP Therapeutic
Flag link:
Acceleron Receives Two FDA Orphan Designations for ACE-536
Acceleron Receives Two FDA Orphan Designations for ACE-536
Yahoo
FDA
orphan drugs
ACE-536
Acceleron
beta-thalassemia
myelodysplastic syndromes
Flag link: